Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer
1996

Effects of Fadrozole in Advanced Breast Cancer

Sample size: 80 publication Evidence: moderate

Author Information

Author(s): HR Bonnefoi, IE Smith, M Dowsett, PF Trunet, SJ Houston, RJ da Luz, RD Rubens, RC Coombe, TJ Powles

Primary Institution: Royal Marsden Hospital and Institute of Cancer Research

Hypothesis

Does fadrozole hydrochloride effectively treat advanced breast cancer in post-menopausal women after tamoxifen failure?

Conclusion

Fadrozole is a clinically active aromatase inhibitor with a low incidence of side effects.

Supporting Evidence

  • The objective response rate was 17% with no complete responders.
  • Fifteen patients (21%) had stable disease and 45 patients (63%) had progressive disease.
  • The median duration of objective response was 36 weeks.
  • The median time to treatment failure was 12.7 weeks.

Takeaway

Fadrozole is a medicine that helps some women with advanced breast cancer feel better, and it doesn't cause many side effects.

Methodology

This was a double-blind, between-patient comparison of three doses of fadrozole hydrochloride in post-menopausal women with recurrent breast cancer.

Potential Biases

Potential selection bias due to the nature of patient recruitment and previous treatments.

Limitations

The study had a small sample size and some patients were not eligible for evaluation.

Participant Demographics

Post-menopausal women under 80 years with recurrent breast cancer after tamoxifen failure.

Statistical Information

Confidence Interval

95% CI 8.9-27.3%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication